Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 882 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period C Clear all
Completed Phase 2Phase 3 Interventional Results available

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

NCT00151775
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Year to 16 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

NCT00509093
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate, gene expression analysis, mutation analysis, polymerase chain reaction, flow cytometry, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Buffalo, New York • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 31, 2026, 7:09 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Sedentary Behavior Interrupted: A Trial of Acute Effects on Biomarkers of Healthy Aging

NCT03511352
View directory record Official record
Conditions
Sedentary Lifestyle
Interventions
Frequent sit-to-stands, Stand More
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
55 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 1 Interventional

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

NCT02891278
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Sertraline, Cytosine arabinoside, allogeneic stem cell transplantation
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants

NCT07102316
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TPIP F2, TPIP F3
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants

NCT07341152
View directory record Official record
Conditions
Pain Management
Interventions
LTG-001 SDD, LTG-001 Formulation A Prototype 1, LTG-001 Formulation B prototype 2
Drug
Lead sponsor
Latigo Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 31, 2026, 7:09 AM EDT
Terminated Phase 3 Interventional

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

NCT06527404
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 2 Interventional

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT04658472
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
SAR445088 (IV), SAR445088 (SC)
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

NCT02723630
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lenvatinib 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 31, 2026, 7:09 AM EDT
Recruiting Phase 2 Interventional

Cognitive Remediation Intervention to Prepare for Transition of Care

NCT05336201
View directory record Official record
Conditions
Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Health-Related Behavior, Coping Skills
Interventions
CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 7:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

NCT00254995
View directory record Official record
Conditions
Meningitis, Meningococcal Disease
Interventions
None administered in this study
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
62,626 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

NCT01894386
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Results available

Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia

NCT00746811
View directory record Official record
Conditions
Primary Hypercholesterolemia
Interventions
P-OM3, Placebo
Drug
Lead sponsor
Provident Clinical Research
Other
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

NCT02056392
View directory record Official record
Conditions
Solid Tumours
Interventions
Selumetinib, Moxifloxacin, selumetinib placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 31, 2026, 7:09 AM EDT
Recruiting Phase 3 Interventional

A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury

NCT07799532
View directory record Official record
Conditions
Chronic Spinal Cord Injury
Interventions
NVG-291, Placebo
Drug
Lead sponsor
NervGen Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Pheonix, Arizona • Downey, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Itraconazole Oral Absorption

NCT04035187
View directory record Official record
Conditions
Fungal Infection
Interventions
fast itraconazole tablet, medium itraconazole tablet, slow itraconazole tablet, oral itraconazole solution
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 1 Interventional

A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

NCT00821054
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Buffalo, New York • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

NCT04877366
View directory record Official record
Conditions
Dietary Supplement
Interventions
Dietary Supplement: Sprinkled Format REDUCOSE., Reference control, Active comparator
Dietary Supplement · Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

NCT06347861
View directory record Official record
Conditions
Healthy
Interventions
single dose of vepdegestrant as tablet formulation (Treatment A), single dose of vepdegestrant as tablet formulation (Treatment B), single dose of vepdegestrant as tablet formulation (Treatment C)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

NCT03438461
View directory record Official record
Conditions
Healthy
Interventions
Seltorexant 40 mg, Seltorexant 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 31, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

A Peer Recovery Coaching Intervention for Hospitalized Alcohol Use Disorder Patients

NCT06479681
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Peer recovery coaching (PRC), Brief Intervention (SBIRT)
Behavioral
Lead sponsor
Clemson University
Other
Eligibility
18 Years to 75 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Greenville, South Carolina • Seneca, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 31, 2026, 7:09 AM EDT
Completed Not applicable Interventional

Mindfulness Based Cognitive Therapy for Youth With Anxiety at Risk for Bipolar Disorder

NCT02090595
View directory record Official record
Conditions
Anxiety, Bipolar Disorder
Interventions
MBCT-C, Waitlist Control
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 31, 2026, 7:09 AM EDT
Not listed Phase 2 Interventional

Reducing Proviral HIV DNA With Interferon-a

NCT02227277
View directory record Official record
Conditions
HIV, HIV/AIDS
Interventions
Peg-IFN-α2b
Drug
Lead sponsor
The Wistar Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 31, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neurobehavioral Changes Following Spaceflight Stressors

NCT07293494
View directory record Official record
Conditions
Stressor, Individual, Alcohol Impairment, Sleep Deprivation, Impairment, Cognitive
Interventions
Alcohol Administration, Sleep Deprivation, Control
Other · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 31, 2026, 7:09 AM EDT